Sector News

Danaher names Martin Stumpe as chief data and AI officer

June 8, 2024
Life sciences

Danaher has appointed Martin Stumpe to the newly created position of chief data and artificial intelligence officer.

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

Stumpe established his healthcare AI credentials at Google, where he founded the cancer pathology project and worked on initiatives such as the application of deep learning to the detection of metastatic breast cancer. At Tempus, Stumpe helped to build an AI and data science department to support activities such as response predictions and biomarker discovery.

Jose-Carlos Gutierrez-Ramos, Danaher’s chief science officer, said in a statement that Stumpe’s “extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting Danaher’s AI and data strategy to advance innovation.”

Danaher discussed its use of AI in its annual financial filing in February. The company said it was in the “initial stages” of incorporating AI into its business activities and product and service offerings. AI is creating new risks, Danaher said. The risks extend beyond flawed algorithms or the use of biased training data.

“Any disruption or failure in the AI functionality we incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our offerings,” Danaher said in the filing. “Conversely, any failure to successfully develop and deploy AI in our business activities, products and services could adversely affect our competitiveness (particularly if our competitors successfully deploy AI in their businesses, products and services).”

The company added that the development and deployment of AI will increase costs and require additional investment.

Danaher plans to hold an event focused on AI in R&D in December.

Source: medtechdive.com

comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach